---
layout: default
title: Aztreonam
parent: 僅模型預測 (L5)
nav_order: 60
evidence_level: L5
indication_count: 10
---

# Aztreonam
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aztreonam: Drug Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Aztreonam (DB00355) is a monobactam β-lactam antibiotic used for gram-negative bacterial infections. The current Evidence Pack contains **no TxGNN predicted indications**, and critical data items — including original indications, mechanism of action, and safety warnings — are not yet populated. A formal repurposing evaluation cannot be completed until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory data retrieved) |
| Predicted New Indication | Not available (no TxGNN output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions generated |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Evaluation Cannot Proceed

The Evidence Pack for Aztreonam is missing three categories of data that are all required before any repurposing claim can be assessed:

**1. No TxGNN predictions generated.** The `predicted_indications` array is empty. Without a model-predicted target indication, there is no candidate hypothesis to evaluate — every downstream section (evidence review, mechanistic rationale, clinical trial mapping) is contingent on this output.

**2. No mechanism of action on record.** The `original_moa` field is flagged as a High-severity data gap. Even if predictions were available, mechanistic plausibility — a core pillar of drug repurposing reasoning — cannot be assessed without knowing how the drug acts at the molecular level.

**3. No structured original indication data.** The `original_indications` array is empty and no Finland (Fimea) marketing authorisations exist. While Aztreonam is generally known as a monobactam antibiotic active against aerobic gram-negative bacteria, no structured or regulatory-sourced indication text is available in this pack to anchor the repurposing analysis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Finland Market Information

Aztreonam is currently **not marketed in Finland**. Zero marketing authorisations are on record with Fimea.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Safety warnings and contraindications are flagged as a Blocking data gap; DDI query returned no results.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predictions and three unresolved data gaps (Blocking: safety warnings; High: MOA; structural: original indications). There is no repurposing hypothesis to evaluate, and safety cannot be assessed for any new indication.

**To proceed, the following is needed:**

- **TxGNN model output** — re-run the prediction pipeline for DB00355 and populate `predicted_indications` with scored candidates
- **Mechanism of action** — query the DrugBank API for Aztreonam's pharmacodynamics and target proteins
- **Package insert safety data** — download and parse the Fimea or TFDA package insert to extract warnings, contraindications, and special population guidance
- **Clarify repurposing scope** — confirm whether the intended direction is infectious disease (e.g., resistant gram-negative pathogens, inhaled formulation for cystic fibrosis), or a cross-therapeutic area repurposing experiment, as this will determine which TxGNN disease namespace to query
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

